SOTIO

Norbert Prenzel, Head of Business Development and Licensing, will be in Munich for the upcoming Germany – China Pharma and Life Sciences Collaboration Forum. He’ll join a panel focused on exploring emerging trends in the global BD&L sector, particularly in high-growth areas like #ADCs and advanced therapies. #DrugDevelopment #BiotechCollaboration #HealthcareInnovation

Our Business Development team is heading to Lisbon later this month for #BIOEuropeSpring and @LSXLeaders. As we continue to advance our pipeline of next-generation #ADCs, we look forward to meeting with potential partners and investors. Please reach out to Martin Vodak or Norbert Prenzel if you’re attending and would like to meet. @EBDGroup #BIOEurope #BiotechPartnering #OncologyInnovation #CancerTherapy #LSX

Understanding the tumor microenvironment is essential for unlocking new therapeutic strategies in #oncology. At the upcoming @EACRnewsTumour Ecosystem: From Mechanisms to Novel Therapeutics Conference, SOTIO Scientist Cecilia Aquino-Perez will present research on tertiary lymphoid structures in HPV-induced cancers, showing how immune architecture within tumors shapes treatment response. We look forward to sharing our work and engaging with fellow scientists, clinicians, and translational researchers driving progress across the oncology community. #EACR26 #CancerResearch #DrugDevelopment

On #InternationalWomensDay, we acknowledge the important contributions of women across SOTIO and the broader R&D community. Their expertise and leadership strengthen our teams and support the development of innovative, patient‑focused #cancer therapies. To learn more about our culture and meet some of the colleagues driving our mission forward, check out this video: linkedin.com/feed/update/ur… #IWD2026 #WomenInSTEM #DrugDevelopment

SOTIO is attending #ESMOSarcoma next week to meet with others working at the forefront of treating #sarcoma, and share the latest exciting data on our ADC in development for sarcoma, SOT106. Please reach out to our colleagues Vivi Boura or Norbert Prenzel if you’re interested in connecting. @myESMO #RareCancers #Oncology #DrugDevelopment

#ColorectalCancer is now the leading cause of cancer-related death among people younger than 50 in the U.S. It’s a critical moment for #ColorectalCancerAwarenessMonth to spread the word and help drive earlier diagnosis and treatment. We’re developing SOT109, a next generation #ADC designed to target CDH17, an antigen that is highly expressed in colorectal cancer and other GI cancers. Check out how ADCs like our SOT109 program work to address cancers like colorectal cancer below. Learn more about colorectal cancer’s rise in the @AmericanCancer recent report: pressroom.cancer.org/under-50-morta… #DrugDevelopment #AntibodyDrugConjugates

In the article below, Chief Scientific Officer, Amy Jensen-Smith, shares her perspective on the urgent unmet need in #sarcoma and why advancing researching in this complex disease area is so critical, especially on #RareDiseaseDay. SOTIO is committed to developing precision-based therapies for sarcoma, exemplified through SOT106, our investigational antibody-drug conjugate (#ADC) targeting LRRC15, a clinically validated target broadly expressed across sarcoma subtypes. 👉 linkedin.com/posts/amy-jens… #RareDiseaseDay2026 #RareDiseases #RareCancers #OncologyDevelopment

This May, Bio€quity Europe, organized by @BioCentury and #EBDGroup, heads to Prague for its 26th year. We’re thrilled to welcome the biotech community to our home city. We’ll be meeting fellow #oncology experts and showcasing how our emerging pipeline, including our #ADC programs, is turning cutting-edge science into new treatment options for difficult-to-treat solid tumors. We’re eager to engage with those shaping this next wave of innovation. Learn more about this year’s event here: conferences.biocentury.com/bioequity-euro… #BIOEquityEurope #DrugDevelopment #CancerResearch

Our team is heading to London to showcase our latest #ADC advancements at the upcoming @World_ADC Event Series in London. Sarka Stehlikova, Director of Biologics Core Technologies, will explore next-generation bispecific ADCs, focusing on improving safety, addressing tumor heterogeneity, and translating functional preclinical data into effective therapies. @HansonWade #WorldADC #WorldADCLondon #DrugDevelopment #CancerResearch

Today, we celebrate #InternationalDayOfWomenAndGirlsInScience. At SOTIO, women scientists play an essential role across our organization, from discovery research to translational and preclinical development for #cancer treatments. Their perspectives, leadership, and commitment are pivotal to advancing innovative, patient-focused therapies and turning scientific insight into real-world impact. Their work helps move promising science forward and brings us closer to delivering meaningful new treatment options for patients. #WomenInScience #WomenInSTEM #CancerResearch #DrugDevelopment

#WorldCancerDay reminds us of the importance of innovation and collaboration in advancing care for patients everywhere. SOTIO is committed to developing novel therapies for patients with #solidtumors, including next-generation #ADCs like SOT106 for the treatment of soft tissue sarcoma and osteosarcoma and SOT109 for the treatment of colorectal and GI cancers. By creating more precise and effective treatment options, we aim to improve outcomes and expand possibles for those living with cancer. Learn more about our work here: sotio.com/pipeline/sotio… #CancerResearch #OncologyInnovation #DrugDevelopment #UnitedByUnique

January was a strong start to the year for our CEO Radek Spisek and SOTIO BD team, with valuable discussions across the #biotech and #oncology communities at the @jpmorgan Global Healthcare Conference, the @InformaConnect #BiotechShowcase, and the @SachsAssociates Oncology Innovation Forum. Thank you to everyone who met with us - we look forward to continuing these conversations and exploring future collaboration opportunities. Take a look at some highlights below. #JPM26 #Sachs_OIF #DrugDiscovery #BiotechPartnering #OncologyInnovation

We’re looking forward to the upcoming #PragueOnco conference (pragueonco.cz/en/), where we’ll join conversations on the latest advances in #oncology research. Jitka Fucikova, Senior Scientist, will co-chair and participate in a discussion on emerging insights into immune surveillance in ovarian cancer, exploring how innate and adaptive immune cells work together to shape antitumor responses. #OncologyDevelopment #CancerResearch #jsmePPF

We are excited to share this collaborative publication in @NaturePortfolioCommunications, led by our partners at the @UniBasel_en alongside the SOTIO research team. The study shows that ovarian cancer dramatically alters the omentum, a fatty tissue in the abdomen, when it spreads there. By mapping individual cells in healthy and cancer-affected tissue, researchers found that the cancer reprograms the omentum to support tumor growth. We thank our academic collaborators and all contributing institutions for their scientific excellence and dedication in advancing cancer research: @UniSpitalBasel, @ETH_en, @ISBSIB, @CharlesUniPRG Read the full text here: pubmed.ncbi.nlm.nih.gov/41397972/ #OncologyResearch #OvarianCancer

We’re heading to San Diego for PepTalk: The Protein Science and Production Week. Sarka Stehlikova, Director of Biologics Core Technologies, will share how SOTIO is developing next-generation bispecific #ADCs. She will explore strategies focused on fine-tuning bispecific approaches to improve efficacy while reducing on-target toxicity, addressing tumor heterogeneity, and bridging functional in vitro findings with in vivo performance. We’re excited to further the discussion on pushing the boundaries of ADC innovation and SOTIO’s leadership in driving these advances forward. #CHIPepTalk #PepTalk2025 #ADCInnovation #OncologyResearch

The Patent Litigation Europe Summit is around the corner, and our Head of IP, Christoph Rehfuess, will be speaking. Christoph’s panel discussion will examine Bolar exemptions and safe harbor provisions, with a focus on how evolving case law and legislative reform are influencing patent enforcement, timing of injunctions, and litigation risk. Check out more from Christoph: linkedin.com/posts/christop… #LitigationSummit #Biotechnology #jsmePPF

Are you motivated by the opportunity to contribute to innovative methods for developing novel cancer treatments? We’re looking for a Junior Scientist to join our Biologics Core Technologies (BCT) lab at SOTIO. This is an exciting chance to become part a of our team that is responsible for designing our investigational drug candidates. Details about the position can be found below: linkedin.com/jobs/search/?c… and on our website: sotio.com/career/junior-… To learn more about our culture and what it’s like to work at SOTIO, check out the video below. #Biotechnology #OncologyResearch #Hiring #LifeScienceHiring #jsmePPF

#JPM26 is approaching, and we look forward to meeting investors and pharmaceutical partners to explore collaborations on our next-generation therapies for hard-to-treat #cancers. Please reach out to schedule a meeting. @jpmorgan #JPM2026 #HealthcareInnovation #OncologyDevelopment